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• Selection and emergence of naturally occurring or 
therapeutic induced HBV variants with mutations Summary
The emergence and takeover of hepatitis B virus (HBV) variants
carrying mutation(s) in the preS/S genomic region is a fairly fre-
quent event that may occur spontaneously or may be the conse-
quence of immunoprophylaxis or antiviral treatments. Selection
of preS/S mutants may have relevant pathobiological and clinical
implications. Both experimental data and studies in humans
show that several speciﬁc mutations in the preS/S gene may
induce an imbalance in the synthesis of the surface proteins
and their consequent retention within the endoplasmic reticulum
(ER) of the hepatocytes. The accumulation of mutated surface
proteins may cause ER stress with the consequent induction of
oxidative DNA damage and genomic instability. Viral mutants
with antigenically modiﬁed surface antigen may be potentially
infectious to immune-prophylaxed patients and may account
for cases of occult HBV infection. In addition, preS/S variants were
reported to be associated with cases of fulminant hepatitis as
well as of ﬁbrosing cholestatic hepatitis, and they are associated
with cirrhosis and hepatocellular carcinoma development.
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by Elsevier B.V. Open access under CC BY-NC-ND license.in the preS/S genomic region is a frequent event in 
chronically HBV infected patientsDespite the availability of an effective vaccine, hepatitis B virus
• S-escape variants may be undetectable by the 
commercially available HBsAg assays and are 
potentially capable of infecting properly immune-
prophylaxed patients, and they may also account for 
cases of occult HBV infection
• Several specific mutations in the preS/S gene may 
induce an unbalanced production of envelope proteins 
that accumulate in the endoplasmic reticulum (ER) Introduction
(HBV) infection remains a major health problem worldwide with
estimates of nearly 400 million chronic HBV surface antigen
(HBsAg) carriers. HBV infection may be associated with a large
spectrum of clinical manifestations, ranging from very mild and
asymptomatic clinical forms to the most severe liver diseases
including fulminant hepatitis, cirrhosis, and hepatocellular carci-
noma (HCC) [1]. The variation of the natural course of the infection
and related disease is determined by the interaction between virusJournal of Hepatology 20
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pathic and host immune responses against viral antigens is consid-
ered the main cause of hepatocellular injury [2]. However, several
linesof evidence indicate thata certainnumberofHBVgeneticvari-
ants, apparently provided with higher pathogenicity, may emerge
during the course of the infection under endogenous (host immu-
nity) and/or exogenous (immunoprophylaxis and antiviral thera-
pies) selection pressures [3]. In this context, a growing number of
studies performed in different geographic areas – thus evaluating
differentHBVgenotypes– arepointing out the considerable impor-
tance of HBV envelope proteinmutants (preS/S variants) including
those able to escape the vaccine-induced anti-HBV neutralizing
antibodies aswell as those frequently associatedwith severe forms
of acute and chronic liver disease and hepatocellular carcinoma
(HCC)development [4–16]. Aimof this reviewwas to revise the col-
lection of data on the biological and clinical impacts of preS/S HBV
variants, also stressing the aspects that are widely accepted by the
scientiﬁc community and those that are still debated.of the hepatocytes, and may activate the ER stress-
signaling pathways with consequent induction of 
oxidative DNA damage and genomic instability
• The cytotoxic effects exerted by the intracellular 
accumulation of surface proteins can contribute to 
liver damage, favoring the progression of the disease 
toward cirrhosis and the development of HCC
14 vol. 61 j 408–417
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Fig. 1. Schematic representation of the hepatitis B virion. The virion consists of
an envelope containing three related surface proteins (S-, M-, and L-proteins) and
lipids, an icosahedral nucleocapsid that is constituted by the core protein (HBcAg)
and that encloses the viral DNA genome covalently linked to the terminal protein
of the viral polymerase.
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HBV virology
HBV is one of the smallest viruses in nature and its genome pre-
sents a highly compact genetic organization. It consists of a relaxed
circular partially double-stranded DNA (rcDNA) of approximately
3200 nucleotides and comprises four partially overlapping
open-reading frames (ORF): preS/S, preCore/Core, Pol, andX. There
are nonon-coding sequences in the viral genomeandall regulatory
regions (enhancer II/basal core promoter, preS1 promoter,
preS2/S promoter, enhancer I/X promoter) are also part of
protein-encoding sequences. The PreS/SORF encodes the three dif-
ferent, structurally related envelope proteins, which are synthe-
sized from alternative initiation codons and are termed Large (L),
Middle (M), and Small (S) protein, respectively. The three proteins
share the same carboxy-terminus part but have different amino-
terminal extensions. In particular, the S-protein – corresponding
to theHBsAg – consists of only 226 amino acids (aa), theM-protein
contains an extra N-terminal extension of 55 aa, whereas the
L-protein has a further N-terminal sequence of 108 or 119 aa –
depending on the genotype – compared to the M-protein [17]
(Fig. 1).
Envelope proteins contain themajor viral antigenic domains. In
particular, the immunodominant determinant bearing the anti-
HBs neutralization domain, termed ‘‘a’’ determinant, has been
mapped to amino acids 99–170 of the S-protein [17,18]. The
preS/S ORF completely overlaps with the Pol ORF, which encodes
the viral polymerase, a multifunctional protein that possesses
reverse transcriptase, DNA-dependent DNA polymerase, and
RNase H activities, and also functions as a terminal protein for
priming. The pre-Core/Core and X ORFs overlap with the Pol ORF
only in part. The pre-Core/Core region encodes the structural pro-
tein of the viral nucleocapsid (the hepatitis B core antigen, HBcAg)
and the non-structural secreted hepatitis B e protein (HBeAg).
These two viral proteins also derive from alternative initiation of
translation at two in-frame initiation codons. TheX region encodes
the small regulatory X protein, which is essential for viral replica-
tion, and can directly and indirectly modulate host and viral gene
expression [17,19].
Upon infection of hepatocytes, the HBV rcDNA is converted by
cellular enzymes into a covalently closed circular DNA (cccDNA)
inside the cells nuclei. Episomal HBV cccDNA persists in the hepa-
tocyte as a stableminichromosome organized by histone and non-
histone proteins. The viral minichromosome utilizes the cellular
transcriptional machinery to produce all viral RNAs necessary for
protein production and viral replication, which requires reverse
transcription of the pregenomic RNA (pgRNA) [20]. Unlike retrovi-
ruses, HBVdoes not need to integrate its DNA into the host genome
to replicate. Nonetheless, HBV DNA integration occurs frequently
during the course of viral infection, and the integrated viral
sequences, being usually deleted or rearranged, are replication-
incompetent and differ from each other in size and structure
[21]. Following transcription, all viral RNAs are transported to
and translated in the cytoplasm. The nucleocapsid protein HBcAg,
the soluble secreted HBeAg and the Pol protein are produced from
the 3.5-kb pgRNA/pre-Core RNAs; the L envelope protein from the
2.4-kb RNA; the M and S envelope proteins from the 2.1-kb RNA;
the X-protein from the 0.7 kb RNA. In the cytosol, the 3.5 kb
pgRNA – apart from being transcribed – is selectively incorporated
into progeny nucleocapsids and reverse transcribed by the co-
assembled viral polymerase into new HBV genomes [19]. The
mature rcDNA-containingnucleocapsids can then either re-deliver
their genomes to the nucleus to build up a pool of around 10–100Journal of Hepatology 201copies cccDNA [22] or can interact with the envelope proteins at
ER/Golgi apparatus and be secreted as new infectious virions
[23]. Envelope protein synthesis follows a pathway that is distinct
from viral replication. It occurs in the ER and leads to amounts of
proteins that far exceed those required for virion assembly. Excess
envelope proteins undergo dimerization and multimerization
resulting in their budding from the ER/Golgi compartment as both
non-infectious spherical and ﬁlamentous subviral particles (SVP)
or as virions. The SVPs typically outnumber the virions by a factor
of 1,000- to 10,000-fold, they may be components of circulating
immune complexes [24], and may induce immune tolerance by a
mechanism of ‘‘viral apoptotic-like mimicry’’ [25]. HBsAg is the
most abundant protein in SVPs as well as in virions, whilst the
M- and L-protein constitute approximately 20% of the total enve-
lope proteins present in the HBV particles [26]. Of note, the com-
mercial HBsAg quantiﬁcation assays available target all forms of
circulating envelope proteins, since the antibodies used in the
quantitative immunoassays identify epitopes in the S domain,
and are not capable of distinguishing between virion-associated
HBsAg and subviral particles or HBsAg produced by possible inte-
grated HBV sequences [27].
The L, M, and S proteins perform different functions during
viral morphogenesis and release, and their speciﬁc roles appear
to be strictly related to their transmembrane topology. In partic-
ular, the L envelope protein shows two transmembrane topolo-
gies. In fact, the preS1 domain of the L protein can be either
projected towards the cytoplasm or oriented towards the ER
lumen. This is consistent with the different and essential func-
tions fulﬁlled by the preS1 domain in the HBV life cycle, given
that the cytoplasmic fraction performs a matrix-like function in
nucleocapsid envelopment, and the fraction that faces the ER
lumen ends up exposed on the viral surface of mature viral par-
ticles and is involved in the attachment of HBV to hepatocytes
[23,28]. HBV polymerase lacks a proofreading function, thus the
reverse transcription step results in the selection of HBV
quasispecies containing several mutations within their viral gen-
ome. Indeed, HBV exhibits a mutation rate more than 10-fold
higher than other DNA viruses. Mutations accumulating in
individual genomes reﬂect both the duration of active HBV
infection and the strength of the immune response. Moreover,
apart from viral and host factors, exogenously induced selection4 vol. 61 j 408–417 409
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Fig. 2. Types and positions of mutations affecting the preS/S region that are selected under the pressure of host immunity, immunoprophylaxis, and antiviral
therapy. At the top is a schematic representation of the overlap between the polymerase and the envelope open reading frames, showing that mutations in one reading
frame can affect the other. The numbers indicate amino acid (aa) sites. Numbering is according to genotype D. The ‘‘a’’ determinant of HBsAg that is located between aa 99
and 170, and which includes the major antibody neutralization domain of HBV, is indicated. Deletions are shown by dashed boxes. Up-down dashed arrows indicate
resistance mutations in the polymerase gene that result in viral envelope changes leading to escape to anti-HBs antibodies and altered virion secretion. The X symbol
indicates the abolition of the preS2 start codon. The ⁄ symbol indicates a stop codon.
Reviewpressures (immunoprophylaxis and antiviral therapy) may
strongly affect substitution rates in HBV [3]. Some of these muta-
tions are detrimental to the virus while others may provide the
virus with a survival advantage. Several studies have shown that
these HBV mutations are not distributed randomly over the
entire genome but rather tend to cluster in particular portions
of the viral DNA as the basal core promoter (BCP)/preCore region
and the preS/S region [29].
In particular, the preS1 and preS2 regions appear to be the
most variable sequences of the viral genome. Indeed, HBV vari-
ants with point mutations, deletions, or insertions in the preS
sequences are often found in patients with long-lasting chronic
hepatitis B (CHB) [29] (Fig. 2). Among these variants those defec-
tive in synthesizing the M protein appear to be the most fre-
quently selected [4–10,30–32]. Actually, whereas L and S
proteins are essential for the HBV life cycle, the M protein is
unnecessary for virion formation, secretion, and infectivity, as
shown both by in vitro and in vivo studies [10,33,34]. In fact,
the preS2 genomic region overlaps the spacer domain of the P
gene, which can tolerate mutations and large deletions without
affecting the polymerase activity [35]. In this context, it has to
be remembered that the complete overlap of the preS/S ORF by
the polymerase gene may create conditions in which changes
within the S gene – naturally selected or selected as a conse-
quence of immunotherapies such as HBV vaccination or prophy-
laxis with hepatitis B immune globulin (HBIg) – can cause410 Journal of Hepatology 201functionally signiﬁcant alterations of the viral polymerase possi-
bly affecting viral replication ﬁtness (Fig. 2). Similarly, changes
selected within the polymerase coding region as a consequence
of nucleos(t)ide analogue (NA) therapy may result in structural
changes in HBsAg, with consequent modiﬁcations of the anti-
genic properties of this protein [36]. Furthermore, it is worth
mentioning that the process of intracellular recycling of newly
synthesized rcDNA-containing nucleocapsids [37,38] apart from
involving rcDNA molecules with naturally selected mutations
arisen in the course of error-prone reverse transcription can also
enclose those molecules selected under immune and/or drug
pressure which all end up being archived into the nuclear cccDNA
pool [39] (Fig. 2).
It has recently been demonstrated that infection with preS/S
mutants may be associated with signiﬁcantly lower levels of cir-
culating HBsAg in CHB patients, and that cells replicating preS/S
mutants isolated from patients, in addition to harboring envelope
proteins in the ER, had reduced amounts of HBsAg in the super-
natant and an increased accumulation of cccDNA molecules into
the nuclei [40]. Actually, a large amount of evidence indicates
that a modiﬁed ratio between envelope proteins is associated
with an impaired secretion of virions and SVPs [41–44] and with
a signiﬁcant increase of cccDNA copy numbers per hepatocyte
[45–48]. A determined relative molar ratio of L to S protein is,
in fact, essential for correct assembly and release of replicating
viral particles [44,45,49] as well as for the control of cccDNA4 vol. 61 j 408–417
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formation rates [45–50]. Of importance, it has been shown that
failure in the regulation of the size of cccDNA pool may result
in hepatocyte death [48,51,52]. Therefore, a balanced expression
of envelope proteins appears to be vital for the HBV life cycle as
well as for maintenance of the non-cytopathic virus-cell
relationship.Clinical signiﬁcance of HBV preS/S genetic variants
PreS/S mutations as cause of immune escape HBV and occult HBV
infection
The beneﬁcial effect of the available anti-HBV vaccine in prevent-
ing new infection is evident worldwide and particularly in highly
endemic areas [36,53,54]. Analogously well recognized, however,
is the possible emergence of HBV genetic variants that are able to
elude the control of the speciﬁc vaccine-induced anti-HBs anti-
bodies [55–57]. The identiﬁcation of HBV vaccine escape mutants
was ﬁrstly reported in the early ’90s in an Italian child born to an
HBsAg/HBeAg positive mother [12]. This child developed chronic
HBV infection despite having received correct passive-active
immunoprophylaxis and having developed anti-HBs antibodies,
thus being theoretically protected against the virus. Many subse-
quent studies from different areas of the world largely conﬁrmed
that ﬁrst observation, reporting the identiﬁcation of individuals
who developed HBV infection in spite of having had vaccine-
induced circulating anti-HBs antibodies [11,58–60]. In the major-
ity of cases, the HBV vaccine escape variants carry point nucleo-
tide mutations causing amino acid substitution in the ‘‘a’’
determinant of the HBsAg and particularly the arginine to glycine
substitution at aa position 145 [61,62]. In other cases, additional
mutations have been recognized, and in particular a unique in-
frame insertion of 2 to 8 aa between codon position 121 and
124 – just upstream of the ﬁrst loop of the ‘‘a’’ determinant –
has been detected, an insertion that may considerably modify
the conformational status of the ‘‘a’’ determinant [63–65]. The
same escape variants may emerge and take over from patients
with graft infection after liver transplantation for HBV-related
diseases who receive immunoprophylaxis with high doses of
monoclonal or polyclonal hepatitis B speciﬁc HBIg [15,16,66–
68]. As mentioned above, the Pol gene completely overlaps the
S gene, and consequently, drug-resistant HBV mutants emerging
under antiviral therapy with NA inhibitors of the viral reverse
transcriptase may also carry mutations in the S protein causing
alteration of its antigenicity [3,36,53,69–73]. Of note, although
HBV mutants with altered envelope antigenicity are mostly
‘‘therapeutically’’ induced variants (since selection occurs under
active or passive immunoprophylaxis or antiviral treatments),
they may also emerge spontaneously because viral strains with
mutations in the ‘‘a’’ determinant or surrounding it have also
been isolated from individuals naïve to any immunoprophylaxis
or antiviral treatment [74–77]. In this context, however, the pos-
sibility cannot be ruled out that some of these individuals have
been infected with HBsAg-mutated viruses from subjects – the
source of the infection – in whom the mutants had emerged
under therapy. In fact, there is considerable evidence that the
‘‘a’’ determinant variants may be viable and pathogenic [78,79]
and that they may infect properly vaccinated people [59,80–
84]. At present, contrasting data are available on the incidence
of infection with the S-escape variants [11,13,85], but it is clearJournal of Hepatology 201that their possible spread would have considerable consequences
in terms of public health, and the establishment of surveillance
programs to monitor the emergence and possible clinical effects
of these variants has thus been recommended [53,72].
Furthermore, apart from the ability to avoid neutralization by
both vaccine-induced and HBIg anti-HBs, these HBV variants may
also account for cases of occult HBV infection (OBI). In fact,
although OBI is more often related to suppression of HBV replica-
tion and gene expression by host defense mechanisms [86], there
is also much evidence of occult HBV infection due to actively rep-
licating viruses able to elude the recognition by the commercially
available HBsAg detection kits in different settings of HBsAg-neg-
ative patients [87]. This issue is of utmost importance for the risk
of transmission of HBV infection [61,86,88,89]. Noteworthy, the
main cause of the residual cases of HBV transmission by blood
transfusion appears to be essentially related to the lack of recog-
nition of an infection with HBV S-escape mutants of the donor
[90–95]. Even more importantly, HBsAg-mutant strains were
reported to be involved in the cases of de novo HBV infection
occurring in properly vaccinated children who underwent liver
transplantation [96], as well as in many cases of OBI in children
born to HBsAg-positive mothers in spite of effective prophylaxis
with vaccination and HBIg [97]. Of course, long-term follow up
of these children is needed to evaluate the possible clinical rele-
vance – if any – of this conceptually intriguing observation [98].
PreS/S mutants in acute and chronic hepatitis B
S and much more frequently preS HBV mutants have been found
in association with different, severe forms of acute and chronic
liver disease, including fulminant hepatitis (FH), ﬁbrosing chole-
static hepatitis (FCH) and cirrhosis. Actually, emergence and
selection of preS variants is a fairly common event in HBV chron-
ically infected patients. The genetic defects are usually due to (a)
in-frame deletions of different sizes involving the carboxy termi-
nus of the preS1 region or (b) the middle part of the preS2 region,
(c) to point mutation(s) involving the start codon of the preS2
genomic region with consequent complete abolishment of the
M protein synthesis [4–6,10,30,31,40,99–101].
Transmission of HBV preS-mutants, particularly those unable
to synthesize the M protein, has been reported to be associated
with cases of FH. In this context, in the late ‘90s we had the
chance to examine isolates from serially collected serum samples
from a surgeon and his mother, who was accidentally infected by
the son: both died of FH. The infecting viruses were genetically
almost identical in both patients and carried a double nucleotide
mutation in the start codon of the preS2 region that prevented
the synthesis of the corresponding protein, as also conﬁrmed by
immunoassay experiments (of note, the virus isolates from both
patients had wild-type preCore and BCP sequences in the early
phases of the infections) [10]. Moreover, we detected preS2-
defective mutants in additional cases of FH and similar ﬁndings
were subsequently reported by other authors [102,103].
Although experimental studies deﬁnitively conﬁrming the sus-
pected role of preS2-defective HBV in the pathogenesis of the
acute liver failure are still lacking, it is noteworthy to mention
that intracellular retention of HBV surface proteins was found
to be associated with FH in a transgenic mouse model showing
panlobular necrosis and hepatic failure as a consequence of the
extreme sensitivity of hepatocytes with HBV surface protein
retention to interferon-gamma produced by the cytotoxic T4 vol. 61 j 408–417 411
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lymphocytes [104]. In analogy, one might hypothesize that simi-
lar events may also occur in patients newly infected with viruses
unable to encode the M protein and then overproducing and
accumulating L protein in the hepatocytes. Still speculating about
the possible involvement of preS2-defective mutants in the
severe course of acute hepatitis B, one might also hypothesize
that, since the T- and B-cell immunities speciﬁc for the M protein
are important early events in the human immune response to
HBV infection [2], the absence of this protein may result in inef-
ﬁcient neutralization of the virus, favoring the more severe
course of the infection.
In analogy, infection with preS variants causing an imbalance
of surface protein synthesis and consequent intracellular accu-
mulation of proteins and viral particles has been found to be
associated with cases of FCH a very severe and rapidly progres-
sive form of cholestatic liver disease that may occur in HBV
infected immunocompromised patients including liver, kidney,
and bone-marrow transplanted individuals [105–107]. The histo-
logical pattern characterized by a negligible inﬂammatory com-
ponent and a massive presence of viral antigens in the
hepatocytes has led to the hypothesis of a direct cytopathic effect
of the virus in these cases [108–111], a hypothesis that has also
been conﬁrmed by in vitro experiments [106,112]. Noteworthy,
however, the advent of speciﬁc treatment preventing active
HBV reinfection in individuals undergoing liver transplantation
has proved to be very effective in also preventing FCH develop-
ment in these patients.
The intracellular accumulation of viral proteins and replica-
tive intermediates that may follow the emergence and takeover
of preS mutants may therefore be cytotoxic in itself representing
an additional, possible mechanism of liver injury that may con-
tribute to worsen the outcome of the CHB [113]. In fact, a fairly
large number of studies have reported a signiﬁcant association
between infection with preS mutants and cirrhosis [9,114], also
conﬁrmed in the few prospective studies performed in the ﬁeld
so far [7]. In this context, the evidence suggesting that ‘‘complex
HBV variants’’ with combined mutations at level of the preS and
BCP regions are a stronger risk factor than variants mutated in a
single region for CHB progression toward cirrhosis appears of rel-
evance [6,7].
PreS/S mutants and HCC
A recent meta-analysis that included 43 studies and evaluated a
total of 11,582 HBV-infected patients has demonstrated that
infection with preS mutants is associated with 3.77-fold
increased risk of HCC [32]. Actually, data from a prospective
study had already revealed the predictive value of the preS dele-
tion mutants in the development of HCC [7], and a large number
of experimental and clinical studies had provided strong evidence
on the potential role of HBV preS mutants in the pathogenesis of
HCC (Fig. 3) [7,9,14,115–128].
HBV variants more commonly associated with HCC include
preS2-defective viruses with mutations at the level of the preS2
start codon and/or deletions in the 50-terminal half of the preS2
region and preS1 mutated viruses with deletions in the 30-termi-
nal half of the preS1 region [9,14,129,130]. The deleted sequences
often correspond to viral regions containing B or T cells epitopes
[2], therefore preS HBV mutants may represent selected immune
escape HBV variants [3,130]. As mentioned above, both preS1 and
preS2 mutations can determine an unbalanced production of412 Journal of Hepatology 201envelope proteins with a consequent accumulation of mutated
L protein in the ER of hepatocytes, resulting in the activation of
the ER stress signaling pathway [14,41, 42,44,113,115,117,124,
131–134]. It has been proposed that, through the ER stress, large
amounts of reactive oxygen species are generated and cause oxi-
dative DNA damage, and genomic instability, and ultimately
result in HCC development [14,116,126,135,136]. Numerous data
from experimental studies in transgenic mice and cell cultures
appear to conﬁrm the potential pro-oncogenic role of mutated
envelope proteins [14,115,118–120,124,135,137,138]. Interest-
ingly, ground-glass hepatocytes (GGHs) characterized by marked
accumulation of viral surface proteins in ER and considered to be
the histological hallmark of chronic HBV infection [139] have
been recently recognized as precursor lesions of HCC [14,
131–134,137]. At least two different types of GGHs have been
deﬁned and associated with different stages of chronic HBV
infection. Type I GGHs – harboring mutated L protein with dele-
tions over the preS1 region – display a globular or inclusion-like
immunostaining pattern of HBsAg and are typical of the high viral
replicative phase of chronic HBV infection, whereas type II GGHs
– harboring mutants with deletions over the preS2 region or
lacking preS2 starting codon (preS2 mutants) – show marginal
staining patterns of HBsAg, are distributed in large clusters
because of their higher proliferative activity and are characteris-
tic of the advanced stages of chronic liver disease [14]. It has been
observed that the ER stress response induced by preS mutated
proteins is responsible for the enhanced expression of vascular
endothelial growth factor-A (VEGF-A) and for the activation of
Akt/mammalian target of rapamycin (Akt/mTOR) signaling in
GGHs [137]. Apart from the induction of ER stress signals, it has
been shown that preS2 mutated proteins may directly interact
with the Jun activation domain-binding protein 1 (JAB1),
thus triggering cyclin-dependent kinase (Cdk) inhibitor p27 deg-
radation, Retinoblastoma hyperphosphorylation and cell cycle
progression [136]. The preS2 mutants may also induce the
overexpression of both cyclin A and cyclooxygenase-2, thereby
leading to cell cycle progression, cell proliferation, and anchor-
age-independent growth [124,126,135]. Furthermore, in livers
of preS2 mutant-transgenic mice it has been shown that cyclin
A is located in the cytoplasm rather than in the nucleus and that
this aberrantly expressed form of cyclin A is implicated in centro-
some overduplication, which represents a potential mechanism
for chromosome instability [124,126] (Fig. 3).
The preS/S genomic region when deleted in the C-terminus
portion (which includes the viral transmembrane hydrophobic
region III of the S domain) may produce C-terminally truncated
M proteins (MHBst) that are retained and accumulated in the
ER, and may display transcriptional activation properties and
transforming potentials [118–120]. It is noteworthy that preS/S
sequences deleted at the 3’-end and producing functionally active
MHBst have been found in many viral integrates from HBV-asso-
ciated HCCs [121,122,140–142], and experimental data from
transgenic mice and hepatoma cell cultures have shown that
MHBst proteins retained in the ER can trigger a PKC dependent
activation of c-Raf-1/MEK/Erk2 signal transduction cascade,
which leads to the induction of AP-1 and NF-jB transcription fac-
tors, and to an enhanced proliferative activity of hepatocytes
[119,143]. MHBst proteins may also induce an increased cleavage
of procaspases-3 and -9, thus rendering hepatocytes more sus-
ceptible to TRAIL-induced apoptosis [144]. Of interest, the activa-
tor function of the MHBst regulatory protein does not appear to4 vol. 61 j 408–417
Fig. 3. Schematic representation of the proposed models for hepatocellular carcinogenesis associated with the HBV preS/S mutant proteins. The preS mutants can
activate both endoplasmic reticulum (ER) stress-dependent and ER stress-independent signals. PreS1 and preS2 mutations may cause overproduction and accumulation of
mutated envelope proteins in the ER, resulting in signiﬁcant ER stress that may induce DNA damage and genomic instability. The ER stress initiated by the preS mutants can
activate the calcium-dependent protease l-calpain that in turn causes the cleavage of cyclin A resulting in an N-terminus-truncated product that translocates into the
cytoplasm and causes centrosome overduplication. The preS mutants-induced ER stress may also activate different signal pathways involving both nuclear factor NF-kB to
upregulate cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) to activate Akt/mammalian target of Rapamycin (mTOR) signaling. Moreover,
pathways protecting the hepatocytes from apoptosis can be also activated by preS mutants. The preS2 mutants can additionally promote hepatocyte proliferation by
inducing an ER stress-independent activation of a signal transduction pathway that involves the Jun activation domain-binding protein 1 (JAB1), the cyclin-dependent
kinase (Cdk) inhibitor p27, and the Retinoblastoma tumor suppressor. Finally, truncated preS2 protein – functioning as a transactivator – can directly interact with the
hTERT promoter and up-regulate telomerase activity or may activate ERK2 and render hepatocytes susceptible to TRAIL-induced apoptosis.
JOURNAL OF HEPATOLOGYbe linked to the ER stress response but rather to the peculiar
topology of its preS2 domain [143]. Indeed, whereas the preS2
domain of the structural M protein normally faces the lumen of
the ER, the preS2 domain of the MHBst activator protein is direc-
ted toward the cytoplasm [145]. It has been shown that the preS2
domain facing the cytoplasm may directly interact with cytosolic
binding proteins, thereby triggering intracellular signal transduc-
tion cascades [28,119,145]. Of interest, it has also been reported
that MHBst may upregulate human telomerase reverse transcrip-
tase (hTERT) expression. Intriguingly, a truncated form of preS2
protein appears to be able to directly interact with a preS2-
responsive DNA region and can activate the hTERT promoter,
resulting in the upregulation of telomerase activity and in the
promotion of HCC development [120] (Fig. 3). Importantly, hTERT
has been found highly expressed in preS2-positive human HCC
samples [120].
It is worth mentioning that apart from the chromosomal inte-
grated HBV sequences, C-terminally truncated surface proteins
can also be produced by non-integrated viral variants that emerge
under the selective pressure of the host’s immune response and/orJournal of Hepatology 201antiviral treatment [40,69,75,138,146–148]. In particular, various
studies have reported that infections with mutated HBV strains
with premature stop codon at position 172 or 182 of the S gene
are signiﬁcantly associated with cirrhosis and HCC
[69,138,146,148]. In addition and of particular interest, in patients
whounderwentprolonged antiviral therapywithNAs such as lam-
ivudine or adefovir the possible selection of a resistantHBVvariant
showing the A181T mutation in the viral polymerase and a stop
codon in the overlapping S gene at amino acid 172 (sW172⁄) has
been described, which results in the deletion of the last 55 amino
acids of the C-terminal hydrophobic region of the surface proteins
[69,138,147,148] (Fig. 2 and Table 1). Various studies have demon-
strated that this variant has a secretory defect and may transacti-
vate different oncogene promoters [138,148]. Of interest, it has
also been shown that NIH3T3 cells stably expressing the sW172⁄
preS/S mutant have increased tumorigenicity in nude mice
[138,148]. The direct oncogenic potential of the rtA181T/sW172⁄
HBV variant has been invoked to explain the fact that long-term
therapy with NAs (particularly, when started with lamivudine
monotherapy) may reduce, but does not deﬁnitely eliminate, the4 vol. 61 j 408–417 413
Table 1. Major drug-resistant mutations selected in the HBV reverse-trans-
criptase (rt) and leading to the generation of stop codons in HBsAg.
Nucleos(t)ide 
analogs
Resistance 
mutations
S gene nonsense 
mutations 
Adefovir
Lamivudine
Telbivudine
rtA181T sW172- stop
Entecavir rtT184M sL176-stop
Lamivudine
Telbivudine
rtM204I sW196-stop
Reviewrisk ofHCCdevelopment inCHBpatients [149,150]. Indeed, there is
evidence indicating that the rate of HCC is particularly high in lam-
ivudine resistant patients and that among cirrhotics, the incidence
of HCC is signiﬁcantly higher in patients with lamivudine resis-
tance than in those who are NAs naïve [149]. Of interest, some
recent studies have reported that deletions in the preS2 genomic
region tend to be co-selected with the drug resistance–associated
mutations in lamivudine treated patients, and that the preS2 geno-
mic changes do not confer drug-resistance but play a supportive
role in the replication of lamivudine-resistant viruses [30,151].
In this context, the observation that CHB patients – in partic-
ular if cirrhotics – maintain a quite high risk of developing HCC
even under efﬁcient NA therapy with persistent and long-lasting
negative serum HBV DNA is of great relevance [152–155]. As
mentioned above, NAs suppress the viral replication but have
no effect on the S gene transcription and surface protein synthe-
sis, thus making it possible to speculate that the persistence of
HBV oncogenicity in the context of an efﬁcient antiviral therapy
might be related to the persistence of the oxidative stress exerted
by the surface proteins accumulated in the hepatocytes. Prospec-
tive studies are needed to verify this hypothesis.Conclusions
Selection of naturally occurring or therapeutic induced HBV vari-
ants carrying mutations at the level of one or more of the three in
frame coding regions of the viral preS/S gene is a fairly frequent
event in chronically HBV infected patients. These mutations are
invariably associated with changes in the HBV Polymerase gene
that completely overlaps the S-ORF. Several of these variants
may have important clinical impacts. Mutations at the level of
the ‘‘a’’ determinant of the S protein may lead to the production
of an antigenically modiﬁed S protein that may not be recognized
by the speciﬁc anti-HBs neutralizing antibody, thus rendering
these S-escape variants potentially capable of infecting properly
immune-prophylaxed patients. In addition, these variants with
an antigenically modiﬁed S protein may be undetectable by the
commercially available HBsAg assays and they may account for
cases of occult HBV infection. Deletions in the preS1 or in the
preS2 genomic regions, mutations abolishing the preS2 start
codon or inserting stop codons in the S genomic region may
determine an unbalance in the synthesis of all envelope proteins
with an overproduction and an intracellular accumulation of the
L protein, which in turn may interfere with the secretion of the S
protein and the viral particles. In this context, the observation
that accumulation of L protein in the hepatocytes might have a
direct and deleterious cytopathic effect both in transgenic mice414 Journal of Hepatology 201(which develop FH) and in liver transplanted patients (who
may develop FCH) assumes great relevance. The cytotoxic effects
exerted by the intracellular accumulation of surface proteins
might contribute to liver damage, favoring the progression of
the disease toward cirrhosis. In fact, relevant evidence has dem-
onstrated that frequencies of the preS mutations consecutively
increase during the progression of chronic HBV infection from
the asymptomatic HBV carrier state to liver cirrhosis or HCC. It
has been shown that hepatocytes harboring modiﬁed L and M
surface proteins have a potential growth advantage. They assume
the typical aspect of type II GGHs, which frequently cluster in
nodules because of their higher proliferative activity and poten-
tial clonal expansion. There are several possible hepatocarcino-
genic effects of preS/S mutations. The overproduction and
accumulation of mutated L and M surface proteins in the ER is
the cause of signiﬁcant ER stress with the consequent induction
of oxidative DNA damage and genomic instability. Furthermore,
truncated preS2/S sequences have been proposed to enhance
tumor development by encoding a protein with transcriptional
transactivation activity. Therefore it appears of the utmost
importance that patients with chronic hepatitis B are screened
for the presence of preS/S mutant infection. The detection of
these speciﬁc HBV variants may indeed be useful for the identiﬁ-
cation of those patients requiring a preventive and appropriate
treatment and a more intensive follow-up strategy for early
detection of HCC.Financial support
Authors have received ﬁnancial grants supporting their studies
on HBV-related hepatocarcinogenesis by the Associazione Itali-
ana per la Ricerca sul Cancro (AIRC, grant n. IG12022) and their
studies on HBV preS/S genetic variants by Gilead Sciences (Gilead
Fellowship PROGRAM 8A508d9d89).Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.References
[1] Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486–1500.
[2] Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev
Immunol 1995;13:29–60.
[3] Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther
2010;15:3–14.
[4] Pollicino T, Campo S, Raimondo G. PreS and core gene heterogeneity in
hepatitis B virus (HBV) genomes isolated from patients with long-lasting
HBV chronic infection. Virology 1995;208:672–677.
[5] Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, et al. Prevalence and
signiﬁcance of hepatitis B virus (HBV) pre-S mutants in serum and liver at
different replicative stages of chronic HBV infection. Hepatology
2001;33:277–286.
[6] Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and
mapping of pre-S deletion in hepatitis B virus carriers with progressive liver
diseases. Gastroenterology 2006;130:1153–1168.
[7] Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, et al. Pre-S deletion
and complex mutations of hepatitis B virus related to advanced liver
disease in HBeAg-negative patients/sb:maintitle>. Gastroenterology
2007;133:1466–1474.4 vol. 61 j 408–417
JOURNAL OF HEPATOLOGY
[8] Choi MS, Kim DY, Lee DH, Lee JH, Koh KC, Paik SW, et al. Clinical signiﬁcance
of pre-S mutations in patients with genotype C hepatitis B virus infection. J
Viral Hepat 2007;14:161–168.
[9] Raimondo G, Costantino L, Caccamo G, Pollicino T, Squadrito G, Cacciola I,
et al. Non-sequencing molecular approaches to identify preS2-defective
hepatitis B virus variants proved to be associated with severe liver diseases.
J Hepatol 2004;40:515–519.
[10] Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, et al. Pre-S2
defective hepatitis B virus infection in patients with fulminant hepatitis.
Hepatology 1997;26:495–499.
[11] Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene
mutants of hepatitis B virus in infants who develop acute or chronic
infections despite immunoprophylaxis. Hepatology 1997;26:786–791.
[12] Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al.
Vaccine-induced escape mutant of hepatitis B virus. Lancet
1990;336:325–329.
[13] Lai MW, Lin TY, Tsao KC, Huang CG, Hsiao MJ, Liang KH, et al. Increased
seroprevalence of HBV DNA with mutations in the s gene among
individuals greater than 18 years old after complete vaccination. Gastro-
enterology 2012;143:400–407.
[14] Wang HC, Huang W, Lai MD, Su IJ. Hepatitis B virus pre-S mutants,
endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci
2006;97:683–688.
[15] Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum
Buschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis
B surface antigen is selected by high-dose hepatitis B immune globulin
after liver transplantation. Hepatology 1998;27:254–263.
[16] Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al.
Hepatitis B virus S mutants in liver transplant recipients who were
reinfected despite hepatitis B immune globulin prophylaxis. Hepatology
1998;27:213–222.
[17] Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev
2000;64:51–68.
[18] Norder H, Courouce AM, Magnius LO. Molecular basis of hepatitis B virus
serotype variations within the four major subtypes. J Gen Virol
1992;73:3141–3145.
[19] Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus
Res 2008;134:235–249.
[20] Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control
of cccDNA function in hepatitis B virus infection. J Hepatol
2009;51:581–592.
[21] Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in
the pathogenesis of human hepatocellular carcinoma. J Hepatol
2005;42:760–777.
[22] Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, Summers J. Single-cell
analysis of covalently closed circular DNA copy numbers in a hepadnavirus-
infected liver. Proc Natl Acad Sci U S A 2003;100:12372–12377.
[23] Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterol
2007;13:65–73.
[24] Madalinski K, Burczynska B, Heermann KH, Uy A, Gerlich WH. Analysis of
viral proteins in circulating immune complexes from chronic carriers of
hepatitis B virus. Clin Exp Immunol 1991;84:493–500.
[25] Vanlandschoot P, Leroux-Roels G. Viral apoptotic mimicry: an immune
evasion strategy developed by the hepatitis B virus? Trends Immunol
2003;24:144–147.
[26] Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H,
Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s
sequence. J Virol 1984;52:396–402.
[27] Locarnini S, Bowden S. Hepatitis B surface antigen quantiﬁcation: not what
it seems on the surface. Hepatology 2012;56:411–414.
[28] Schadler S, Hildt E. HBV life cycle: entry and morphogenesis. Viruses
2009;1:185–209.
[29] Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and
common mutants. Semin Liver Dis 2003;23:5–20.
[30] Zhang D, Dong P, Zhang K, Deng L, Bach C, Chen W, et al. Whole genome
HBV deletion proﬁles and the accumulation of preS deletion mutant during
antiviral treatment. BMC Microbiol 2012;12:307.
[31] Santantonio T, Jung MC, Schneider R, Fernholz D, Milella M, Monno L, et al.
Hepatitis B virus genomes that cannot synthesize pre-S2 proteins occur
frequently and as dominant virus populations in chronic carriers in Italy.
Virology 1992;188:948–952.
[32] Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, et al. Associations between hepatitis B
virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J
Natl Cancer Inst 2009;101:1066–1082.Journal of Hepatology 201[33] Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus
assembly. Proc Natl Acad Sci U S A 1991;88:1059–1063.
[34] Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious
hepatitis B virus variant defective in pre-S2 protein expression in a chronic
carrier. Virology 1993;194:137–148.
[35] Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al.
Nomenclature for antiviral-resistant human hepatitis B virus mutations in
the polymerase region. Hepatology 2001;33:751–757.
[36] Torresi J. The virological and clinical signiﬁcance of mutations in the
overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol
2002;25:97–106.
[37] Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected
with duck hepatitis B virus, the template for viral RNA synthesis is
ampliﬁed by an intracellular pathway. Virology 1990;175:255–261.
[38] Zoulim F. New insight on hepatitis B virus persistence from the study of
intrahepatic viral cccDNA. J Hepatol 2005;42:302–308.
[39] Zoulim F. Mechanism of viral persistence and resistance to nucleoside and
nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res
2004;64:1–15.
[40] Pollicino T, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, Cutroneo G, et al.
Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface
antigen and HBV DNA serum levels. Hepatology 2012;56:434–443.
[41] Chisari FV, Filippi P, McLachlan A, Milich DR, Riggs M, Lee S, et al.
Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis
B surface antigen secretion in transgenic mice. J Virol 1986;60:880–887.
[42] Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, et al.
Structural and pathological effects of synthesis of hepatitis B virus large
envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A
1987;84:6909–6913.
[43] Persing DH, Varmus HE, Ganem D. Inhibition of secretion of hepatitis B
surface antigen by a related presurface polypeptide. Science
1986;234:1388–1391.
[44] Bock CT, Tillmann HL, Manns MP, Trautwein C. The pre-S region determines
the intracellular localization and appearance of hepatitis B virus. Hepatol-
ogy 1999;30:517–525.
[45] Summers J, Smith PM, Huang MJ, Yu MS. Morphogenetic and regulatory
effects of mutations in the envelope proteins of an avian hepadnavirus. J
Virol 1991;65:1310–1317.
[46] Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT. Characterization of
the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an
intermediate of covalently closed circular DNA formation. J Virol
2007;81:12472–12484.
[47] Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA:
removal of genome-linked protein. J Virol 2007;81:6164–6174.
[48] Summers J, Smith PM, Horwich AL. Hepadnavirus envelope proteins
regulate covalently closed circular DNA ampliﬁcation. J Virol
1990;64:2819–2824.
[49] Lentz TB, Loeb DD. Roles of the envelope proteins in the ampliﬁcation of
covalently closed circular DNA and completion of synthesis of the plus-
strand DNA in hepatitis B virus. J Virol 2011;85:11916–11927.
[50] Kock J, Rosler C, Zhang JJ, Blum HE, Nassal M, Thoma C. Generation of
covalently closed circular DNA of hepatitis B viruses via intracellular
recycling is regulated in a virus speciﬁc manner. PLoS Pathog
2010;6:e1001082.
[51] Lenhoff RJ, Summers J. Construction of avian hepadnavirus variants with
enhanced replication and cytopathicity in primary hepatocytes. J Virol
1994;68:5706–5713.
[52] Lenhoff RJ, Luscombe CA, Summers J. Acute liver injury following infection
with a cytopathic strain of duck hepatitis B virus. Hepatology
1999;29:563–571.
[53] Torresi J. Hepatitis B antiviral resistance and vaccine escape: two sides of
the same coin. Antivir Ther 2008;13:337–340.
[54] Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of
hepatitis B infection by a 25-year universal vaccination program. J Hepatol
2012;57:730–735.
[55] Gerlich WH. Breakthrough of hepatitis B virus escape mutants after
vaccination and virus reactivation. J Clin Virol 2006;36:S18–S22.
[56] Hollinger FB. Hepatitis B virus genetic diversity and its impact on
diagnostic assays. J Viral Hepat 2007;14:11–15.
[57] Gerlich WH, Glebe D, Schuttler CG. Deﬁciencies in the standardization and
sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat
2007;14:16–21.
[58] Chiou HL, Lee TS, Kuo J, Mau YC, Ho MS. Altered antigenicity of ‘a’
determinant variants of hepatitis B virus. J Gen Virol 1997;78:2639–2645.4 vol. 61 j 408–417 415
Review
[59] Francois G, Kew M, Van Damme P, Mphahlele MJ, Meheus A. Mutant
hepatitis B viruses: a matter of academic interest only or a problem with
far-reaching implications? Vaccine 2001;19:3799–3815.
[60] Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global
control of hepatitis B virus: does treatment-induced antigenic change affect
immunization? Bull World Health Organ 2010;88:66–73.
[61] Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and
diagnostic impact. J Clin Virol 2005;32:102–112.
[62] Pawlotsky JM. The concept of hepatitis B virus mutant escape. J Clin Virol
2005;34:S125–S129.
[63] Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, et al.
Naturally occurring escape mutants of hepatitis B virus with various
mutations in the S gene in carriers seropositive for antibody to hepatitis B
surface antigen. J Virol 1994;68:2671–2676.
[64] Hou J, Karayiannis P, Waters J, Luo K, Liang C, Thomas HC. A unique
insertion in the S gene of surface antigen–negative hepatitis B virus Chinese
carriers. Hepatology 1995;21:273–278.
[65] Kato J, Hasegawa K, Torii N, Yamauchi K, Hayashi N. A molecular analysis of
viral persistence in surface antigen-negative chronic hepatitis B. Hepatol-
ogy 1996;23:389–395.
[66] McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpin
MD, et al. Genetic alterations in the gene encoding the major HBsAg:
DNA and immunological analysis of recurrent HBsAg derived from
monoclonal antibody-treated liver transplant patients. Hepatology
1992;15:757–766.
[67] Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G,
et al. Hepatitis B virus envelope variation after transplantation with and
without hepatitis B immune globulin prophylaxis. Hepatology 1996;24:
489–493.
[68] Hawkins AE, Gilson RJ, Gilbert N, Wreghitt TG, Gray JJ, Ahlers-de Boer I,
et al. Hepatitis B virus surface mutations associated with infection after
liver transplantation. J Hepatol 1996;24:8–14.
[69] Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients
receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010;15:
471–475.
[70] Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide
analogues. Gastroenterology 2009;137:e1–e2.
[71] Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral
therapy. J Antimicrob Chemother 2008;61:766–768.
[72] Chang MH. Breakthrough HBV infection in vaccinated children in Taiwan:
surveillance for HBV mutants. Antivir Ther 2010;15:463–469.
[73] Hsu CW, Yeh CT, Chang ML, Liaw YF. Identiﬁcation of a hepatitis B virus S
gene mutant in lamivudine-treated patients experiencing HBsAg seroclea-
rance. Gastroenterology 2007;132:543–550.
[74] Liu CJ, Kao JH, Shau WY, Chen PJ, Lai MY, Chen DS. Naturally occurring
hepatitis B surface gene variants in chronic hepatitis B virus infection:
correlation with viral serotypes and clinical stages of liver disease. J Med
Virol 2002;68:50–59.
[75] Pollicino T, Isgro G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, et al.
Variability of reverse transcriptase and overlapping S gene in hepatitis B
virus isolates from untreated and lamivudine-resistant chronic hepatitis B
patients. Antivir Ther 2009;14:649–654.
[76] Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, et al. Prevalence of naturally
occurring surface gene variants of hepatitis B virus in nonimmunized
surface antigen-negative Chinese carriers. Hepatology 2001;34:
1027–1034.
[77] De Maddalena C, Giambelli C, Tanzi E, Colzani D, Schiavini M, Milazzo L,
et al. High level of genetic heterogeneity in S and P genes of genotype D
hepatitis B virus. Virology 2007;365:113–124.
[78] Ogata N, Zanetti AR, Yu M, Miller RH, Purcell RH. Infectivity and
pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus
that emerged in a vaccinated infant. J Infect Dis 1997;175:511–523.
[79] Song BC, Kim SH, Kim H, Ying YH, Kim HJ, Kim YJ, et al. Prevalence of
naturally occurring surface antigen variants of hepatitis B virus in Korean
patients infected chronically. J Med Virol 2005;76:194–202.
[80] Harrison TJ, Zuckerman AJ. Variants of hepatitis B virus. Vox Sang
1992;63:161–167.
[81] Locarnini SA. Hepatitis B virus surface antigen and polymerase gene
variants: potential virological and clinical signiﬁcance. Hepatology
1998;27:294–297.
[82] Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B
viral mutations. Hepatology 2000;31:1037–1044.
[83] Kajiwara E, Tanaka Y, Ohashi T, Uchimura K, Sadoshima S, Kinjo M, et al.
Hepatitis B caused by a hepatitis B surface antigen escape mutant. J
Gastroenterol 2008;43:243–247.416 Journal of Hepatology 201[84] Thakur V, Kazim SN, Guptan RC, Hasnain SE, Bartholomeusz A, Malhotra V,
et al. Transmission of G145R mutant of HBV to an unrelated contact. J Med
Virol 2005;76:40–46.
[85] Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, et al. No increase in
prevalence of hepatitis B surface antigen mutant in a population of children
and adolescents who were fully covered by universal infant immunization.
J Infect Dis 2010;201:1192–1200.
[86] Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin
Immunopathol 2013;35:39–52.
[87] Biswas S, Candotti D, Allain JP. Speciﬁc amino acid substitutions in the S
protein prevent its excretion in vitro and may contribute to occult hepatitis
B virus infection. J Virol 2013;87:7882–7892.
[88] Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing
D, et al. Escape hepatitis B virus mutations in recipients of antibody to
hepatitis B core antigen-positive liver grafts receiving hepatitis B immu-
noglobulins. Liver Transpl 2010;16:885–894.
[89] Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus
infection. J Hepatol 2007;46:160–170.
[90] Huang CH, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, et al. Inﬂuence of
mutations in hepatitis B virus surface protein on viral antigenicity and
phenotype in occult HBV strains from blood donors. J Hepatol
2012;57:720–729.
[91] Hollinger FB. Hepatitis B virus infection and transfusion medicine: science
and the occult. Transfusion 2008;48:1001–1026.
[92] Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J
Hepatol 2009;51:798–809.
[93] Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, et al.
Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med
2011;364:236–247.
[94] Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J
Viral Hepat 2010;17:1–15.
[95] Allain JP, Cox L. Challenges in hepatitis B detection among blood donors.
Curr Opin Hematol 2011;18:461–466.
[96] Su WJ, Ho MC, Ni YH, Wu JF, Jeng YM, Chen HL, et al. Clinical course of de
novo hepatitis B infection after pediatric liver transplantation. Liver Transpl
2010;16:215–221.
[97] Shahmoradi S, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri
SM. High prevalence of occult hepatitis B virus infection in children born to
HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination
and HBIG. J Hepatol 2012;57:515–521.
[98] Yeh CT, Lai MW. Eliminating hepatitis B virus through neonatal vaccina-
tion: can we make it? J Hepatol 2012;57:484–485.
[99] Gerken G, Kremsdorf D, Petit MA, Manns M, Meyer zum Buschenfelde KH,
Brechot C. Hepatitis B defective virus with rearrangements in the preS gene
during HBV chronic infection. J Hepatol 1991;13:S93–S96.
[100] Melegari M, Bruno S, Wands JR. Properties of hepatitis B virus pre-S1
deletion mutants. Virology 1994;199:292–300.
[101] Tai PC, Suk FM, Gerlich WH, Neurath AR, Shih C. Hypermodiﬁcation and
immune escape of an internally deleted middle-envelope (M) protein of
frequent and predominant hepatitis B virus variants. Virology
2002;292:44–58.
[102] Sterneck M, Gunther S, Gerlach J, Naoumov NV, Santantonio T, Fischer L,
et al. Hepatitis B virus sequence changes evolving in liver transplant
recipients with fulminant hepatitis. J Hepatol 1997;26:754–764.
[103] Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus
population defective in virus secretion because of several S-gene mutations
from a patient with fulminant hepatitis. Hepatology 2001;34:385–394.
[104] Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, et al.
Mechanisms of class I restricted immunopathology. A transgenic mouse
model of fulminant hepatitis. J Exp Med 1993;178:1541–1554.
[105] Trautwein C, Schrem H, Tillmann HL, Kubicka S, Walker D, Boker KH, et al.
Hepatitis B virus mutations in the pre-S genome before and after liver
transplantation. Hepatology 1996;24:482–488.
[106] Bock CT, Tillmann HL, Maschek HJ, Manns MP, Trautwein C. A preS
mutation isolated from a patient with chronic hepatitis B infection leads to
virus retention and misassembly. Gastroenterology 1997;113:1976–1982.
[107] Zanati SA, Locarnini SA, Dowling JP, Angus PW, Dudley FJ, Roberts SK.
Hepatic failure due to ﬁbrosing cholestatic hepatitis in a patient with pre-
surface mutant hepatitis B virus and mixed connective tissue disease
treated with prednisolone and chloroquine. J Clin Virol 2004;31:53–57.
[108] Thung SN. Histologic ﬁndings in recurrent HBV. Liver Transpl
2006;12:S50–S53.
[109] Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic
spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol 2008;1:
396–402.4 vol. 61 j 408–417
JOURNAL OF HEPATOLOGY
[110] Lau JY, Bain VG, Davies SE, O’Grady JG, Alberti A, Alexander GJ, et al. High-
level expression of hepatitis B viral antigens in ﬁbrosing cholestatic
hepatitis. Gastroenterology 1992;102:956–962.
[111] Mason AL, Wick M, White HM, Benner KG, Lee RG, Regenstein F, et al.
Increased hepatocyte expression of hepatitis B virus transcription in
patients with features of ﬁbrosing cholestatic hepatitis. Gastroenterology
1993;105:237–244.
[112] Foo NC, Ahn BY, Ma X, Hyun W, Yen TS. Cellular vacuolization and
apoptosis induced by hepatitis B virus large surface protein. Hepatology
2002;36:1400–1407.
[113] Bruss V. Revisiting the cytopathic effect of hepatitis B virus infection.
Hepatology 2002;36:1327–1329.
[114] Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, et al.
Inﬂuence of hepatitis B virus genotypes on the development of preS
deletions and advanced liver disease. J Med Virol 2003;70:537–544.
[115] Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, et al.
Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus
transgenic mice. Cell 1989;59:1145–1156.
[116] Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, et al.
Extensive oxidative DNA damage in hepatocytes of transgenic mice with
chronic active hepatitis destined to develop hepatocellular carcinoma. Proc
Natl Acad Sci U S A 1994;91:12808–12812.
[117] Huang SN, Chisari FV. Strong, sustained hepatocellular proliferation
precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic
mice. Hepatology 1995;21:620–626.
[118] Hildt E, Hofschneider PH. The PreS2 activators of the hepatitis B virus:
activators of tumour promoter pathways. Recent Results Cancer Res
1998;154:315–329.
[119] Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2
activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in
transgenic mice. EMBO J 2002;21:525–535.
[120] Luan F, Liu H, Gao L, Liu J, Sun Z, Ju Y, et al. Hepatitis B virus protein preS2
potentially promotes HCC development via its transcriptional activation of
hTERT. Gut 2009;58:1528–1537.
[121] Schluter V, Meyer M, Hofschneider PH, Koshy R, Caselmann WH. Integrated
hepatitis B virus X and 30 truncated preS/S sequences derived from human
hepatomas encode functionally active transactivators. Oncogene
1994;9:3335–3344.
[122] Zhong S, Chan JY, Yeo W, Tam JS, Johnson PJ. Hepatitis B envelope protein
mutants in human hepatocellular carcinoma tissues. J Viral Hepat
1999;6:195–202.
[123] Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, et al. Pre-S mutant
surface antigens in chronic hepatitis B virus infection induce oxidative
stress and DNA damage. Carcinogenesis 2004;25:2023–2032.
[124] Wang HC, Chang WT, Chang WW, Wu HC, Huang W, Lei HY, et al. Hepatitis
B virus pre-S2 mutant upregulates cyclin A expression and induces nodular
proliferation of hepatocytes. Hepatology 2005;41:761–770.
[125] Yeung P, Wong DK, Lai CL, Fung J, Seto WK, Yuen MF. Association of
hepatitis B virus pre-S deletions with the development of hepatocellular
carcinoma in chronic hepatitis B. J Infect Dis 2011;203:646–654.
[126] Wang LH, Huang W, Lai MD, Su IJ. Aberrant cyclin A expression and
centrosome overduplication induced by hepatitis B virus pre-S2 mutants
and its implication in hepatocarcinogenesis. Carcinogenesis 2012;33:
466–472.
[127] Huang HP, Hsu HY, Chen CL, Ni YH, Wang HY, Tsuei DJ, et al. Pre-S2
deletions of hepatitis B virus and hepatocellular carcinoma in children.
Pediatr Res 2010;67:90–94.
[128] Chen CH, Changchien CS, Lee CM, Hung CH, Hu TH, Wang JH, et al.
Combined mutations in pre-s/surface and core promoter/precore regions of
hepatitis B virus increase the risk of hepatocellular carcinoma: a case-
control study. J Infect Dis 2008;198:1634–1642.
[129] Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of
view of the hepatitis B virus. Carcinogenesis 2011;32:1122–1132.
[130] Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus
Res 2007;127:164–176.
[131] Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. Different types of ground
glass hepatocytes in chronic hepatitis B virus infection contain speciﬁc pre-
S mutants that may induce endoplasmic reticulum stress. Am J Pathol
2003;163:2441–2449.
[132] Su IJ, Wang HC, Wu HC, Huang WY. Ground glass hepatocytes contain pre-S
mutants and represent preneoplastic lesions in chronic hepatitis B virus
infection. J Gastroenterol Hepatol 2008;23:1169–1174.
[133] Tsai HW, Lin YJ, Lin PW, Wu HC, Hsu KH, Yen CJ, et al. A clustered ground-glass
hepatocyte pattern represents a new prognostic marker for the recurrence of
hepatocellular carcinoma after surgery. Cancer 2011;117:2951–2960.Journal of Hepatology 201[134] Mathai AM, Alexander J, Kuo FY, Torbenson M, Swanson PE, Yeh MM. Type
II ground-glass hepatocytes as a marker of hepatocellular carcinoma in
chronic hepatitis B. Hum Pathol 2013;44:1665–1671.
[135] Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT, et al. Endoplasmic
reticulum stress stimulates the expression of cyclooxygenase-2 through
activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol
Chem 2004;279:46384–46392.
[136] Hsieh YH, Su IJ, Wang HC, Tsai JH, Huang YJ, Chang WW, et al. Hepatitis B
virus pre-S2 mutant surface antigen induces degradation of cyclin-depen-
dent kinase inhibitor p27Kip1 through c-Jun activation domain-binding
protein 1. Mol Cancer Res 2007;5:1063–1072.
[137] Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, et al. Enhanced
expression of vascular endothelial growth factor-A in ground glass
hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis.
Hepatology 2009;49:1962–1971.
[138] Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/
surface truncation mutant. Antivir Ther 2008;13:875–879.
[139] Hadziyannis S, Gerber MA, Vissoulis C, Popper H. Cytoplasmic hepatitis B
antigen in ‘‘ground-glass’’ hepatocytes of carriers. Arch Pathol
1973;96:327–330.
[140] Caselmann WH, Meyer M, Kekule AS, Lauer U, Hofschneider PH, Koshy R. A
trans-activator function is generated by integration of hepatitis B virus
preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad
Sci U S A 1990;87:2970–2974.
[141] Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R.
The preS2/S region of integrated hepatitis B virus DNA encodes a
transcriptional transactivator. Nature 1990;343:457–461.
[142] Hildt E, Saher G, Bruss V, Hofschneider PH. The hepatitis B virus large
surface protein (LHBs) is a transcriptional activator. Virology
1996;225:235–239.
[143] Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J
Gastroenterol 2007;13:74–81.
[144] Liang X, Du J, Liu Y, Cui M, Ma C, Han L, et al. The hepatitis B virus protein
MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through
ERK2. Apoptosis 2007;12:1827–1836.
[145] Hildt E, Urban S, Hofschneider PH. Characterization of essential domains
for the functionality of the MHBst transcriptional activator and identiﬁca-
tion of a minimal MHBst activator. Oncogene 1995;11:2055–2066.
[146] Lee SA, Kim K, Kim H, Kim BJ. Nucleotide change of codon 182 in the
surface gene of hepatitis B virus genotype C leading to truncated surface
protein is associated with progression of liver diseases. J Hepatol
2012;56:63–69.
[147] Warner N, Locarnini S. The antiviral drug selected hepatitis B virus
rtA181T/sW172⁄ mutant has a dominant negative secretion defect and
alters the typical proﬁle of viral rebound. Hepatology 2008;48:88–98.
[148] Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT. Identiﬁcation of
nonsense mutations in hepatitis B virus S gene in patients with hepato-
cellular carcinoma developed after lamivudine therapy. Antivir Ther
2009;14:249–261.
[149] Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of
hepatocellular carcinoma in chronic hepatitis B patients receiving nucle-
os(t)ide therapy: a systematic review. J Hepatol 2010;53:348–356.
[150] Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopou-
lou-Gigi M, Vaﬁadis-Zoumbouli I, et al. Virological suppression does not
prevent the development of hepatocellular carcinoma in HBeAg-negative
chronic hepatitis B patients with cirrhosis receiving oral antiviral(s)
starting with lamivudine monotherapy: results of the nationwide HEPNET
Greece cohort study. Gut 2011;60:1109–1116.
[151] Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, et al.
Supportive role played by precore and preS2 genomic changes in the
establishment of lamivudine-resistant hepatitis B virus. J Infect Dis
2008;198:1150–1158.
[152] Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio
PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation
to virological response to lamivudine. Hepatology 2004;40:883–891.
[153] Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for
patients with chronic hepatitis B and advanced liver disease. N Engl J Med
2004;351:1521–1531.
[154] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,
et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic
hepatitis B for up to 5 years. Gastroenterology 2006;131:1743–1751.
[155] Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low
resistance to adefovir combined with lamivudine: a 3-year study of 145
lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:
1445–1451.4 vol. 61 j 408–417 417
